Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

ABSTRACT:

Background

Ovarian cancer tends to be chemosensitive and confine itself to the surface of the peritoneal cavity for much of its natural history. These features have made it an obvious target for intraperitoneal (IP) chemotherapy. Chemotherapy for ovarian cancer is usually given as an intravenous (IV) infusion repeatedly over five to eight cycles. Intraperitoneal chemotherapy is given by infusion of the chemotherapeutic agent directly into the peritoneal cavity. There are biological reasons why this might increase the anticancer effect and reduce some systemic adverse effects in comparison to IV therapy.

Objectives

To determine if adding a component of the chemotherapy regime into the peritoneal cavity affects overall survival, progression-free survival, quality of life (QOL)

SUBMITTER: Jaaback K 

PROVIDER: S-EPMC8602974 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature